<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9201">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05703074</url>
  </required_header>
  <id_info>
    <org_study_id>983971636</org_study_id>
    <nct_id>NCT05703074</nct_id>
  </id_info>
  <brief_title>Mental Intervention and Nicotinamide Riboside Supplementation in Long Covid</brief_title>
  <acronym>MINIRICO</acronym>
  <official_title>The Efficacy and Safety of a Mental Intervention Program vs. Usual Care and Nicotinamide Riboside (NR) vs. Placebo for Improving Health-related Quality of Life in Long Covid: A 2 x 2 Factorial Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Akershus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Long COVID, also referred to as post-acute sequela of COVID-19 (PASC), is present in a&#xD;
      substantial number of individuals, and treatment for this is warranted. Two different&#xD;
      hypothetical models of Long COVID suggest attenuated mitochondrial energy production and&#xD;
      psychosocial load, respectively, to be key mechanisms in the underlying pathophysiology.&#xD;
      Given the potential importance of metabolic disturbances, dietary supplement by Nicotinamide&#xD;
      Riboside (NR, sales name Niagen®) may be beneficial. Given the potential importance of&#xD;
      psychosocial factors, a tailored and personalized Mind-Body Reprocessing Therapy (MBRT) may&#xD;
      be beneficial. The MBRT consists of 4 to 6 face-to-face therapist encounters in combination&#xD;
      with digital resources.&#xD;
&#xD;
      The primary objective is to determine whether NR 1000 mg twice daily and/or MBRT increase&#xD;
      health-related quality of life in individuals with Long COVID compared with care as usual&#xD;
      and/or placebo. The Medical Outcome Study 36-item short form (SF-36), general health subscore&#xD;
      is the primary endpoint. Secondary endpoints are: Markers of inflammation (hsCRP) and&#xD;
      cognitive function (digit span test), cost-effectiveness, and the patient-reported symptoms&#xD;
      fatigue, dyspnoea, and global impression of change in symptoms, function and quality of life.&#xD;
      Explorative objectives encompass intervention effects on additional cognitive function&#xD;
      markers, biological markers (indices of autonomic nervous activity), disability markers (work&#xD;
      attendance) and patient symptoms, as well as the exploration of long-term effects,&#xD;
      differential subgroup effects, intervention effect mediators and intervention effect&#xD;
      predictors.&#xD;
&#xD;
      The study is a randomized controlled trial featuring a 2 x 2 factorial design where MBRT is&#xD;
      compared with usual care and NR is compared with placebo. The latter comparison is double&#xD;
      blinded. Eligible participants are individuals (18-70 years) with confirmed Long COVID&#xD;
      interferring negatively with daily activities. A total of 310 participants will be enrolled.&#xD;
      After baseline assessment (T1), the participants will be randomized 1:1 for both treatment&#xD;
      comparisons, resulting in four treatment groups: a) MBRT and NR; b) usual care and NR; c)&#xD;
      MBRT and placebo; d) usual care and placebo. All treatments last for three months, followed&#xD;
      by primary endpoint assessment (T2). Total follow-up time is 12 months (T3). A comprehensive&#xD;
      investigational program at all time points includes clinical examination, functional testing&#xD;
      (spirometry, autonomic cardiovascular control, neurocognitive functions), sampling of&#xD;
      biological specimens (blood) and questionnaire charting (background/demographics, clinical&#xD;
      symptoms, psychosocial factors, study events).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2023</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>A 2 x 2 factorial randomized controlled trial, where Mind-Body Reprocessing Therapy (MBRT) is compared with care as usual and Nicotinamide Riboside (NR) is compared with placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>For the NR vs placebo comparison, participants, care providers, investigators and outcome assessors are blinded. For the MBRT vs. usual care comparison, due to the nature of the intervention, only outcome assessors are blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Three months after inclusion (T2)</time_frame>
    <description>The Medical Outcome Study 36-item short form (SF-36), general health subscore (total range 0 - 100, where higher scores indicate better QoL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>Three months after inclusion (T2)</time_frame>
    <description>Plasma levels of C-reactive protein, high-sensitive assay (hsCRP). Higher levels indicate more inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Working memory</measure>
    <time_frame>Three months after inclusion (T2)</time_frame>
    <description>The Digit Span Test, total score, adopted from the Wechsler Adult Intelligence Scale (WAIS), 4th edition (WAIS-IV). Total range is from 0 - 30; higher scores indicate better working memory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>Three months after inclusion (T2)</time_frame>
    <description>Chalder Fatigue Questionnaire (CFQ), total sum score (total range is from 0 - 33; higher scores indicate more fatigue)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnoea</measure>
    <time_frame>Three months after inclusion (T2)</time_frame>
    <description>Medical Research Council dyspnoea scale. Total range is from 1 - 5, where higher scores indicate more dyspnoea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global impression of change</measure>
    <time_frame>Three months after inclusion (T2)</time_frame>
    <description>Patient Global Impression of Change (PGIC) inventory. Total range is from 1 - 7; higher scores imply that the health status is considered worsened</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>Three months after inclusion (T2)</time_frame>
    <description>Incremental cost-effectiveness ratio, using the 36-item short form (SF-36) general health subscore to determine quality-adjusted life years.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Attention bias</measure>
    <time_frame>Three months after inclusion (T2)</time_frame>
    <description>A computerised test of attention bias towards illness-related words</description>
  </other_outcome>
  <other_outcome>
    <measure>Worrying tendencies</measure>
    <time_frame>Three months after inclusion (T2)</time_frame>
    <description>Penn State Worry Questionnaire (PSWQ), total sum score (higher scores means more worrying)</description>
  </other_outcome>
  <other_outcome>
    <measure>Sympathetic predominance</measure>
    <time_frame>Three months after inclusion (T2)</time_frame>
    <description>Heart rate variability (HRV) indices in the time and frequency domain using a 5-minute ECG recording obtained during supine rest</description>
  </other_outcome>
  <other_outcome>
    <measure>Post-exertional malaise (PEM)</measure>
    <time_frame>Three months after inclusion (T2)</time_frame>
    <description>PEM items from the DePaul Symptom Questionnaire, total average score across five items</description>
  </other_outcome>
  <other_outcome>
    <measure>Pain</measure>
    <time_frame>Three months after inclusion (T2)</time_frame>
    <description>Brief Pain Inventory (BPI), average score</description>
  </other_outcome>
  <other_outcome>
    <measure>Sleep difficulties</measure>
    <time_frame>Three months after inclusion (T2)</time_frame>
    <description>Karolinska sleep questionnaire (KSQ), total sum score</description>
  </other_outcome>
  <other_outcome>
    <measure>Depression and anxiety</measure>
    <time_frame>Three months after inclusion (T2)</time_frame>
    <description>Hospital Anxiety and Depression Symptoms (HADS), total sum score</description>
  </other_outcome>
  <other_outcome>
    <measure>Smell and taste</measure>
    <time_frame>Three months after inclusion (T2)</time_frame>
    <description>Assessed by two singel questionnaire items; responses on a 5-point Likert scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Executive functioning</measure>
    <time_frame>Three months after inclusion (T2)</time_frame>
    <description>The trail-making test of neurocognitive functioning</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Long COVID</condition>
  <arm_group>
    <arm_group_label>MBRT and NR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Psychological therapy and dietary supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MBRT and placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Psychological therapy and placebo dietary supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Care as usual and NR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No psychological therapy (information only) and dietary supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Care as usual and placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No psychological therapy (information only) and placebo dietary supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nicotinamide Riboside (NR)</intervention_name>
    <description>4 capsules (a total of 1000 mg) 2 times daily for 84 days</description>
    <arm_group_label>Care as usual and NR</arm_group_label>
    <arm_group_label>MBRT and NR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Mind-body reprocessing therapy (MBRT)</intervention_name>
    <description>4-6 face-to-face meetings over 3-4 weeks, unlimited access to designated online resources.</description>
    <arm_group_label>MBRT and NR</arm_group_label>
    <arm_group_label>MBRT and placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Care as usual</intervention_name>
    <description>A brief self-help leaflet on long COVID is distributed, otherwise care as usual by the general practitioner</description>
    <arm_group_label>Care as usual and NR</arm_group_label>
    <arm_group_label>Care as usual and placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4 capsules (empty) 2 times daily for 84 days.</description>
    <arm_group_label>Care as usual and placebo</arm_group_label>
    <arm_group_label>MBRT and placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Undergone acute COVID-19, confirmed EITHER by a positive PCR-test OR a positive&#xD;
             self-test combined with confirmatory antibody-pattern in blood.&#xD;
&#xD;
          -  Persistent symptoms at least 6 months following acute COVID-19 without symptom-free&#xD;
             interval.&#xD;
&#xD;
          -  Functional disability to an extent that impacts negatively on normal activities (such&#xD;
             as work attendance, physical exercise, social activities, etc.)&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other chronic illnesses, demanding life situations or concomitant drug use/substance&#xD;
             abuse that is considered a plausible cause of persistent symptoms and associated&#xD;
             disability&#xD;
&#xD;
          -  Sustained organ damage (lung, heart, brain) following acute, serious Covid-19&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Bedridden&#xD;
&#xD;
          -  Insufficient command of Norwegian&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Torbjørn Omland, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Akershus University Hospital/University of Oslo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vegard BB Wyller, PhD</last_name>
    <phone>91166681</phone>
    <phone_ext>+47</phone_ext>
    <email>v.b.b.wyller@medisin.uio.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vegard Wyller Wyller, MD</last_name>
      <phone>91166681</phone>
      <phone_ext>47</phone_ext>
      <email>v.b.b.wyller@medisin.uio.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>January 25, 2023</study_first_submitted>
  <study_first_submitted_qc>January 25, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2023</study_first_posted>
  <last_update_submitted>March 22, 2023</last_update_submitted>
  <last_update_submitted_qc>March 22, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Akershus</investigator_affiliation>
    <investigator_full_name>Vegard Wyller</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Post-Acute COVID-19 Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 25, 2023</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT05703074/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 24, 2023</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT05703074/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

